AbbVieNYSE: ABBV

Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.

Users of Zacks.com have been paying a lot of attention to AbbVie (ABBV) lately. Therefore, it's important to understand the key factors that could influence the stock's future.

Teliso-V is a new type of treatment called an antibody-drug conjugate (ADC) designed for patients with nonsquamous non-small cell lung cancer (NSCLC) who have already received treatment and have high levels of the c-Met protein. The application for fast-track approval is backed by results from the Phase 2 LUMINOSITY trial (M14-239).

Novo Nordisk is a strong company, but its dividend payments are not as remarkable. In comparison, AbbVie has a much better track record when it comes to dividends over the years.

On Thursday, AbbVie announced that its medication achieved the primary objective in a late-stage study involving patients with early Parkinson's disease.

A recent analysis shows that RINVOQ® (upadacitinib) is effective for patients with moderate-to-severe atopic dermatitis, particularly those with varying levels of severity in the head and neck areas. The study found improvements in skin clearance, reduction of itching, and overall quality of life after 16 weeks. AbbVie will present these findings, along with other data from their dermatology portfolio, at the upcoming 33rd European Academy of Dermatology and Venereology Congress in Amsterdam.

If it gets the green light, this will be the first time ABBV's Elahere receives regulatory approval in the European Union.

As a dividend growth investor who prioritizes income, I suggest increasing cash reserves and selling off lower-quality stocks because of possible recession risks. Historical trends indicate that rate cuts usually happen before recessions, so it's wise to boost cash holdings and limit investments in weaker stocks. Although there are some good buying opportunities, I would rather keep cash in ETFs like SGOV for safety and flexibility during uncertain economic periods.

NORTH CHICAGO, Ill., Sept. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive recommendation for the marketing approval of mirvetuximab soravtansine (ELAHERE®). This treatment is intended for adult patients with folate receptor alpha (FRα)-positive, platinum-resistant, and high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone one to three previous treatment courses.